市場調查報告書

胰臟癌症 - 全球市場的未來展望(2017-2026)

Pancreatic Cancer - Global Market Outlook (2017-2026)

出版商 Stratistics Market Research Consulting 商品編碼 907703
出版日期 內容資訊 英文 183 Pages
商品交期: 2-3個工作天內
價格
Back to Top
胰臟癌症 - 全球市場的未來展望(2017-2026) Pancreatic Cancer - Global Market Outlook (2017-2026)
出版日期: 2019年08月19日內容資訊: 英文 183 Pages
簡介

全球胰臟癌症市場在2017年估算為19億420萬美金。今後預測將以10.6%的年複合成長率擴大,2026年達到47億2,819萬美元的規模。

本報告提供胰臟癌症的世界市場調查,市場概要,各類型,終端用戶,地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 摘要整理

第2章簡介

第3章 市場趨勢分析

  • 簡介
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 威脅
  • 終端用戶分析
  • 新興市場
  • 今後的市場方案

第4章 波特的五力分析

  • 供應商談判力
  • 買方議價能力
  • 替代品的威脅
  • 新加入廠商的威脅
  • 產業內的競爭

第5章 胰臟癌症市場:各治療

  • 簡介
  • 生物學的療法
  • 荷爾蒙療法
  • 化療
  • 標靶治療
  • 手術
  • 放射線治療
  • 其他

第6章 胰臟癌症市場:各類型

  • 簡介
  • 外分泌胰臟癌症
  • 內分泌胰臟癌症

第7章 胰臟癌症市場:各終端用戶

  • 簡介
  • 研究所
  • 醫院、診療所
  • 其他

第8章 胰臟癌症市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他
  • 南美
    • 阿根廷
    • 巴西
    • 智利
    • 其他
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他

第9章 主要開發

  • 契約,夥伴關係,聯盟,合資企業
  • 收購與合併
  • 新產品的銷售
  • 擴大策略
  • 其他主要策略

第10章 企業簡介

  • Novartis Ag
  • Eli Lily and Company
  • F. Hoffmann-La Roche AG
  • Pharmacyte Biotech, Inc
  • Clovis Oncology
  • Celgene Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Merck & Co., Inc.
目錄

According to Stratistics MRC, the Global Pancreatic Cancer market is accounted for $1,904.20 million in 2017 and is expected to reach $4,728.19 million by 2026 growing at a CAGR of 10.6% during the forecast period. Advancement of technology in therapeutic devices and expanding prevalence of cancer growth are the factors driving the market. However, accessibility of costly treatment and poor repayment strategies in the emerging regions of the world are some of the factors which may hamper the market growth during the forecast period.

Pancreatic Cancer is a type of cancer that starts in the pancreas. It is a highly lethal disease, for which mortality closely parallels incidence. Most patients with Pancreatic Cancer remain asymptomatic until the disease reaches an advanced stage. There is no standard programme for screening patients at high risk of Pancreatic Cancer. Most Pancreatic Cancers arise from microscopic non-invasive epithelial proliferations within the pancreatic ducts, referred to as pancreatic intraepithelial neoplasias.

Based on the treatment, the biologic therapy has a huge demand due to expanding number of novel upcoming immunotherapies as well as focused cell therapy that treats the cancer with no extreme symptoms and has more number of helpful advantages over the conventional chemotherapies.

By geography, Asia Pacific is growing lucratively during the forecast period owing to the nearness of quickly creating medicinal services innovation, high patient population, and high social insurance use. Additionally, expanding interest for new treatment strategies in nations like India and South Korea is probably going to develop as the quickest developing business sector over the globe.

Some of the key players in the Pancreatic Cancer market include Novartis Ag, Eli Lily and Company, F. Hoffmann-La Roche AG, Pharmacyte Biotech, Inc, Clovis Oncology, Celgene Corporation, Teva Pharmaceutical Industries Ltd., Amgen, Inc., Pfizer, Inc. and Merck & Co., Inc.

Treatments Covered:

  • Biologic Therapy
  • Hormone Therapy
  • Chemotherapy
  • Targeted Therapy
  • Surgery
  • Radiation Therapy
  • Other Treatments

Types Covered:

  • Exocrine Pancreas Cancer
  • Endocrine Pancreas Cancer

End Users Covered:

  • Research Institute
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances.

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pancreatic Cancer Market, By Treatment

  • 5.1 Introduction
  • 5.2 Biologic Therapy
  • 5.3 Hormone Therapy
  • 5.4 Chemotherapy
  • 5.5 Targeted Therapy
  • 5.6 Surgery
  • 5.7 Radiation Therapy
  • 5.8 Other Treatments

6 Global Pancreatic Cancer Market, By Type

  • 6.1 Introduction
  • 6.2 Exocrine Pancreas Cancer
  • 6.3 Endocrine Pancreas Cancer

7 Global Pancreatic Cancer Market, By End User

  • 7.1 Introduction
  • 7.2 Research Institute
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Pancreatic Cancer Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Novartis Ag
  • 10.2 Eli Lily and Company
  • 10.3 F. Hoffmann-La Roche AG
  • 10.4 Pharmacyte Biotech, Inc
  • 10.5 Clovis Oncology
  • 10.6 Celgene Corporation
  • 10.7 Teva Pharmaceutical Industries Ltd.
  • 10.8 Amgen, Inc.
  • 10.9 Pfizer, Inc.
  • 10.10 Merck & Co., Inc.

List of Tables

  • 1 Global Pancreatic Cancer Market Outlook, By Region (2016-2026) (US $MN)
  • 2 Global Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 3 Global Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 4 Global Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 5 Global Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 6 Global Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 7 Global Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 8 Global Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 9 Global Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 10 Global Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 11 Global Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 12 Global Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 13 Global Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 14 Global Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 15 Global Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 16 Global Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
  • 17 North America Pancreatic Cancer Market Outlook, By Country (2016-2026) (US $MN)
  • 18 North America Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 19 North America Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 20 North America Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 21 North America Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 22 North America Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 23 North America Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 24 North America Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 25 North America Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 26 North America Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 27 North America Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 28 North America Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 29 North America Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 30 North America Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 31 North America Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 32 North America Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
  • 33 Europe Pancreatic Cancer Market Outlook, By Country (2016-2026) (US $MN)
  • 34 Europe Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 35 Europe Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 36 Europe Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 37 Europe Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 38 Europe Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 39 Europe Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 40 Europe Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 41 Europe Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 42 Europe Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 43 Europe Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 44 Europe Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 45 Europe Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 46 Europe Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 47 Europe Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 48 Europe Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
  • 49 Asia Pacifc Pancreatic Cancer Market Outlook, By Country (2016-2026) (US $MN)
  • 50 Asia Pacifc Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 51 Asia Pacifc Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 52 Asia Pacifc Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 53 Asia Pacifc Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 54 Asia Pacifc Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 55 Asia Pacifc Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 56 Asia Pacifc Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 57 Asia Pacifc Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 58 Asia Pacifc Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 59 Asia Pacifc Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 60 Asia Pacifc Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 61 Asia Pacifc Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 62 Asia Pacifc Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 63 Asia Pacifc Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 64 Asia Pacifc Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
  • 65 South America Pancreatic Cancer Market Outlook, By Country (2016-2026) (US $MN)
  • 66 South America Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 67 South America Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 68 South America Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 69 South America Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 70 South America Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 71 South America Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 72 South America Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 73 South America Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 74 South America Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 75 South America Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 76 South America Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 77 South America Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 78 South America Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 79 South America Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 80 South America Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
  • 81 Middle East & Africa Pancreatic Cancer Market Outlook, By Country (2016-2026) (US $MN)
  • 82 Middle East & Africa Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 83 Middle East & Africa Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 84 Middle East & Africa Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 85 Middle East & Africa Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 86 Middle East & Africa Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 87 Middle East & Africa Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 88 Middle East & Africa Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 89 Middle East & Africa Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 90 Middle East & Africa Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 91 Middle East & Africa Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 92 Middle East & Africa Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 93 Middle East & Africa Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 94 Middle East & Africa Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 95 Middle East & Africa Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 96 Middle East & Africa Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
Back to Top